ReviewReviews in endocrine & metabolic disorders2018
Myo-inositol in autoimmune thyroiditis, and hypothyroidism.
Review in Reviews in endocrine & metabolic disorders, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 38 citations in OpenAlex.
- Metabolite signature of human malignant thyroid tissue: A systematic review and meta-analysis.Cancer medicine · 2024Pooled it
- Pooled it
- Shared and unique metabolic features of the malignant and benign thyroid lesions determined with use ofScientific reports · 2021Trial
- Unlocking the Therapeutic Potential: Selenium and Myo-Inositol Supplementation in Thyroid Disorders-Efficacy and Future Directions.Life (Basel, Switzerland) · 2025Review
- An exploratory study on the metagenomic and proteomic characterization of hypothyroidism in the first half of pregnancy and correlation with Th1/Th2 balance.Frontiers in immunology · 2025Article
- Autoimmunity, New Potential Biomarkers and the Thyroid Gland-The Perspective of Hashimoto's Thyroiditis and Its Treatment.International journal of molecular sciences · 2024Review
- Role of Supplementation with Selenium and Myo-Inositol Versus Selenium Alone in Patients of Autoimmune Thyroiditis: A Systematic Review and Meta-Analysis.Clinical medicine insights. Endocrinology and diabetes · 2024Article
- Thyroid dysfunction during gestation and gestational diabetes mellitus: a complex relationship.Journal of endocrinological investigation · 2023Review
- Redefining the Cut-Off Ranges for TSH Based on the Clinical Picture, Results of Neuroimaging and Laboratory Tests in Unsupervised Cluster Analysis as Individualized Diagnosis of Early Schizophrenia.Journal of personalized medicine · 2022Article
- Myoinositol in Autoimmune Thyroiditis.Frontiers in endocrinology · 2022Review
- Supplementation with myo-inositol and Selenium improves the clinical conditions and biochemical features of women with or at risk for subclinical hypothyroidism.Frontiers in endocrinology · 2022Article
- Differential lipids in pregnant women with subclinical hypothyroidism and their correlation to the pregnancy outcomes.Scientific reports · 2021Article
- Analysis of metabolomics profile in hypothyroid patients before and after thyroid hormone replacement.Journal of endocrinological investigation · 2021Article
- Precision Medicine in Autoimmune Thyroiditis and Hypothyroidism.Frontiers in pharmacology · 2021Review
- The Role of Inositol in Thyroid Physiology and in Subclinical Hypothyroidism Management.Frontiers in endocrinology · 2021Review
- The Association of Myo-Inositol and Selenium Contrasts Cadmium-Induced Thyroid C Cell Hyperplasia and Hypertrophy in Mice.Frontiers in endocrinology · 2021Article
- D-Chiro-Inositol Improves Sperm Mitochondrial Membrane Potential: In Vitro Evidence.Journal of clinical medicine · 2020Article
- Protective Effects of Myo-Inositol and Selenium on Cadmium-Induced Thyroid Toxicity in Mice.Nutrients · 2020Article
- Chemokines in hyperthyroidism.Journal of clinical & translational endocrinology · 2019Review
- Immunoendocrinology: When (neuro)endocrinology and immunology meet.Reviews in endocrine & metabolic disorders · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myo-inositol (Myo-Ins) plays an important role in thyroid function and autoimmunity. Myo-Ins is the precursor for the synthesis of phosphoinositides, which takes part in the phosphatidylinositol (PtdIns) signal transduction pathway, and plays a decisive role in several cellular processes. In the thyroid cells, PtdIns is involved in the intracellular thyroid-stimulating hormone (TSH) signaling, via Phosphatidylinositol (3,4,5)-trisphosphate (PtdIns(3,4,5)P3) (PIP-3). Moreover, the phosphatidyl inositol 3 kinases (PI3K) family of lipid kinases regulates diverse aspects of T, B, and Tregs lymphocyte behaviour. Different mouse models deficient for the molecules involved in the PIP3 pathway suggest that impairment of PIP3 signaling leads to dysregulation of immune responses and, sometimes, autoimmunity. Studies have shown that cytokines modulate Myo-Ins in thyroid cells. Moreover, clinical studies have shown that after treatment with Myo-inositol plus seleniomethionine (Myo-Ins + Se), TSH levels significantly declined in patients with subclinical hypothyroidism due to autoimmune thyroiditis. The treatment was accompanied by a decline of antithyroid autoantibodies. After treatment serum CXCL10 levels declined, confirming the immune-modulatory effect of Myo-Ins. Additional research is necessary in larger population to evaluate the effect on the quality of life, and to study the mechanism of the effect on chemokines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.